论文部分内容阅读
在危重病患者中经常出现各种严重的心律失常,威胁患者的生命。胺碘酮已被美国FDA批准用于治疗和预防室颤和血流动力学不稳定的室性心律失常及其它抗心律失常药物无效的其它心律失常[1]。胺碘酮在预防心梗及心衰病人的心源性猝死中有较明确的作用[2],我们在危重病
In critically ill patients often appear a variety of serious arrhythmia, threatening the lives of patients. Amiodarone has been approved by the U.S. FDA for the treatment and prevention of ventricular fibrillation and haemodynamically unstable ventricular arrhythmias and other arrhythmias in which antiarrhythmic drugs are ineffective [1]. Amiodarone in the prevention of myocardial infarction and heart failure in patients with sudden cardiac death have a more clear role [2], we in critically ill patients